Adding a New Anticoagulant or Antiplatelet Agent for Patient Receiving Aspirin after an Acute Coronary Syndrome?--Results from a Pairwise and Network Meta-Analysis of Randomized-Controlled Trials

Journal Title: Journal of Advances in Medicine and Medical Research - Year 2015, Vol 6, Issue 2

Abstract

Objectives: To synthesize the efficacy and safety outcomes from randomized-controlled trials (RCTs) regarding new oral anticoagulant, protease-activated receptor-1 (PAR-1) antagonist, and warfarin adjunctive to aspirin for patients after acute coronary syndrome (ACS) via pair-wise and network meta-analyses. Methods: A comprehensive literature search was performed in Embase, Medline, Cochrane Library Web of Knowledge, and Scopus. The pair-wise meta-analysis was undertaken respectively to each agent/treatment category via Revmen 5.1. In order to estimate the relative efficacy of each agent/treatment category whilst preserving the randomized comparisons within each trial, a Bayesian network meta-analysis was conducted in WinBUGS using both fixed- and random-effects model. Covariate analysis was performed to explore the effects of length of follow-up and age of subject on the final results. Results: In total, 23 RCTs were included in the meta-analysis. As shown by the results (OR,95%CI) for the pair-wise meta-analysis, new oral anticoagulants (0.85, [0.78, 0.93] and 3.04, [2.21, 4.19]), PAR-1 antagonists (0.80, [0.52, 1.22] and 1.55, [1.25, 1.93]) and warfarin (0.87, [0.74, 1.02] and 1.77, [1.46, 2.14]) might be able to provide better outcome in the incidences of major adverse events (MAE) but with higher bleeding risk comparing to aspirin treatment alone. Based on the model fit assessment, the random-effects model was adopted. The network meta-analysis (treatment effect comparing to aspirin lone) identified ximelagatran (-0.3044, [-0.8601, 0.2502]), dabigatran (-0.2144, [-0.8666, 0.4525]), rivoroxaban (-0.2179, [-0.5986, 0.1628]) and vorapaxar (-0.2272, [-0.81, 0.1664]) produced better improvements in MAE incidences whereas vorapaxar (0.3764, [-0.4444, 1.124]), warfarin (0.663, [0.3375, 1.037]), ximelagatran (0.7509, [-0.4164, 2.002]) and apixaban (0.8594, [-0.0049, 1.7]) produced less major bleeding events. The indirect comparisons among drug category (difference in incidence comparing to aspirin lone) showed new oral anticoagulants (-0.1974, [-0.284, -0.111]) and PAR-1 antagonists (-0.1239, [-0.215, -0.033]) to besuperior to warfarin (-0.1004, [-0.166, -0.035]) in the occurrences of MAE whereas PAR-1 antagonists (0.4292, [0.2123, 0.6476]) afforded better outcomes in major bleeding events against warfarin (0.5742, [0.3889, 0.7619]) and new oral anticoagulants (1.169, [0.8667, 1.485]). Conclusion: Based on the study results, we cannot recommend the routine administration of new oral anticoagulant as add-on treatment for patients after ACS. However, for ACS patients comorbid with atrial fibrillation, new oral anticoagulant might be superior to warfarin in both efficacy and safety outcomes.

Authors and Affiliations

Lan Gao, Shu-Chuen Li

Keywords

Related Articles

Sex-selective Abortion in Rural Pakistan

Aims: The existence of sex-selective abortions has been documented in Asian countries including Pakistan. However, most of these studies have used indirect methods of estimation based on sex ratio at birth, which is know...

Perception about Working in Rural Area after Graduation and Associated Factors: A Study among Final Year Medical Students in Medical Schools of Southeast Nigeria

Aims: Aim of study was to determine the perception of rural medical practice among final year medical students in medical schools of southeast Nigeria and the associated factors. Study Design: Descriptive cross-sectional...

Impact of Health Centre Nurses on the Reduction of Early Childhood Caries in Lima, Peru

Background: The prevalence of early childhood caries (ECC) among 36-47 months-old children in Lima, Peru, is 65.5%. Dentists have no easy access to see infants but nurses do. If nurses will be trained on oral health beha...

Role of Hepatitis C Virus Infection on Lymphoproliferative Disorders after Non-liver Transplantation

Aims: The number of reports on HCV positive PTLD patients in non-liver transplantation setting as well as our knowledge on the issue is extremely limited. In this study, we aimed to investigate the impact of HCV infectio...

The Prevalence and the Characteristics of Supernumerary Teeth of Children and Young Adolescents from North-Western Region of Turkey

Aim: The objective of the following research is to study the prevalence by evaluating a large group of children and young adolescent patients from the north-western region of Turkey and investigate the characteristics of...

Download PDF file
  • EP ID EP347243
  • DOI 10.9734/BJMMR/2015/14423
  • Views 65
  • Downloads 0

How To Cite

Lan Gao, Shu-Chuen Li (2015). Adding a New Anticoagulant or Antiplatelet Agent for Patient Receiving Aspirin after an Acute Coronary Syndrome?--Results from a Pairwise and Network Meta-Analysis of Randomized-Controlled Trials. Journal of Advances in Medicine and Medical Research, 6(2), 173-199. https://europub.co.uk/articles/-A-347243